MEDICAMEQ
Medicamen Biotech Limited
NSELast Traded Price
₹271.55
-15.6 (-5.48%)
Open
₹286.25
High
₹299.4
Low
₹269
Prev Close
₹284.6
Industry
Pharmaceuticals
Market Cap
364.84 Cr
Filing History
Recent corporate announcements and filings for MEDICAMEQ
Financials
Positive
2026-05-27 15:47
Consolidated Revenue for Q4 FY26 was ₹62.38 Cr vs ₹34.84 Cr (▲79.06% YoY), EBITDA ₹7.18 Cr vs ₹3.62 Cr (▲98.34% YoY), PAT ₹4.45 Cr vs ₹1.86 Cr (▲139.25% YoY). EBITDA Margin was 11.51% vs 10.39% (▲112bps). The Board also recommended a final dividend of Rs. 1.00 per equity share for FY26.
Routine
Neutral
2026-04-06 16:26
Medicamen Biotech Limited clarified an incorrect event displayed on the NSDL portal under its login. The company stated that no such event was initiated or undertaken by them, confirming it as inadvertent and non-material, and is working with NSDL for rectification.
Ownership
Neutral
2026-03-30 12:57
Medicamen Biotech Limited announced the closure of its trading window for designated persons from April 01, 2026, until 48 hours post-declaration of audited financial results for the quarter and year ended March 31, 2026, to prevent insider trading.
Governance
Negative
2026-02-21 16:52
CRITICAL RED FLAG DETECTED
Medicamen Biotech received a cautionary letter from NSE on Jan 27, 2026, for observations reported by the Secretarial Auditor in the Compliance Report for FY2025. The company is advised to be careful to avoid recurrence of lapses, though no impact on financials/operations is expected.
Governance
Neutral
2026-02-18 18:05
Medicamen Biotech Limited issued a corrigendum correcting the retirement date of Independent Directors Mr. Harish Pande and Mr. Arun Kumar from February 13, 2026, to February 26, 2026. They ceased to be directors effective February 26, 2026, due to completion of term.
Governance
Neutral
2026-02-13 16:27
Medicamen Biotech Limited announced that Mr. Harish Pande and Mr. Arun Kumar completed their term as Independent Directors, effective February 13, 2026. They ceased to be part of various committees. New Independent Directors were previously appointed and approved by shareholders.
Financials
Negative
2026-02-13 16:06
CRITICAL RED FLAG DETECTED
Consolidated Revenue ₹4,690.85Cr vs ₹4,514.22Cr (▲4% YoY), EBITDA ₹437.54Cr vs ₹670.55Cr (▼35% YoY), PAT ₹163.47Cr vs ₹292.20Cr (▼44% YoY). EBITDA Margin 9.33% vs 14.85% (▼552bps). Additionally, two independent directors ceased their tenure.
Financials
Negative
2026-02-13 16:03
CRITICAL RED FLAG DETECTED
Consolidated Revenue ₹4,744.34 Lacs vs ₹4,528.29 Lacs (▲4.8% YoY), EBITDA ₹491.03 Lacs vs ₹684.62 Lacs (▼28.3% YoY), PAT ₹163.47 Lacs vs ₹292.20 Lacs (▼44.1% YoY). EBITDA Margin 10.35% vs 15.12% (▼477bps).